Searched for:
(1 - 6 of 6)
document
Verschuren, L. (author), Wielinga, P.Y. (author), Kelder, T. (author), Radonjic, M. (author), Salic, K. (author), Kleemann, R. (author), van Ommen, B. (author), Kooistra, T. (author)
Background : Cardiac pathological hypertrophy is associated with a significantly increased risk of coronary heart disease and has been observed in diabetic patients treated with rosiglitazone whereas most published studies do not suggest a similar increase in risk of cardiovascular events in pioglitazone-treated diabetic subjects. This study...
article 2014
document
Radonjic, M. (author), Wielinga, P.Y. (author), Wopereis, S. (author), Kelder, T. (author), Goelela, V.S. (author), Verschuren, L. (author), Toet, K. (author), van Duyvenvoorde, W. (author), van der Werff van der Vat, B. (author), Stroeve, J.H.M. (author), Cnubben, N. (author), Kooistra, T. (author), van Ommen, B. (author), Kleemann, R. (author)
Excess caloric intake leads to metabolic overload and is associated with development of type 2 diabetes (T2DM). Current disease management concentrates on risk factors of the disease such as blood glucose, however with limited success. We hypothesize that normalizing blood glucose levels by itself is insufficient to reduce the development of...
article 2013
document
Verschuren, L. (author), Radonjic, M. (author), Wielinga, P.Y. (author), Kelder, T. (author), Kooistra, T. (author), van Ommen, B. (author), Kleemann, R. (author)
AIMS: Combination-drug therapy takes advantage of the complementary action of their individual components, thereby potentiating its therapeutic effect. Potential disadvantages include side effects that are not foreseen on basis of the data available from drug monotherapy. Here, we used a systems biology approach to understand both the efficacy...
article 2012
document
Kleemann, R. (author), Bureeva, S. (author), Perlina, A. (author), Kaput, J. (author), Verschuren, L. (author), Wielinga, P.Y. (author), Hurt-Camejo, E. (author), Nikolsky, Y. (author), van Ommen, B. (author), Kooistra, T. (author)
Successful drug development has been hampered by a limited understanding of how to translate laboratory-based biological discoveries into safe and effective medicines. We have developed a generic method for predicting the effects of drugs on biological processes. Information derived from the chemical structure and experimental omics data from...
article 2011
document
Verschuren, L. (author), Wielinga, P.Y. (author), van Duyvenvoorde, W. (author), Tijani, S. (author), Toet, K. (author), van Ommen, B. (author), Kooistra, T. (author), Kleemann, R. (author)
Chronic inflammation and proatherogenic lipids are important risk factors of cardiovascular disease (CVD). Specific dietary constituents such as polyphenols and fish oils may improve cardiovascular risk factors and may have a beneficial effect on disease outcomes. We hypothesized that the intake of an antiinflammatory dietary mixture (AIDM)...
article 2011
document
TNO Kwaliteit van Leven (author), Kleemann, R. (author), van Erk, M. (author), Verschuren, L. (author), van den Hoek, A.M. (author), Koek, M. (author), Wielinga, P.Y. (author), Jie, A. (author), Pellis, L. (author), Bobeldijk-Pastorova, I. (author), Kelder, T. (author), Toet, K. (author), Wopereis, S. (author), Cnubben, N. (author), Evelo, C. (author), van Ommen, B. (author), Kooistra, T. (author)
BACKGROUND: The sequence of events leading to the development of insulin resistance (IR) as well as the underlying pathophysiological mechanisms are incompletely understood. As reductionist approaches have been largely unsuccessful in providing an understanding of the pathogenesis of IR, there is a need for an integrative, time-resolved approach...
article 2010
Searched for:
(1 - 6 of 6)